Covid (other name Movfor)

AntiVirals

Active Ingredient: Molnupiravir

In Stock: Only 26 packs left

Molnupiravir, an Oral Antiviral Treatment for COVID-19

Diseases: Disease 2019

Covid (other name Movfor) other names: Bexovid Covid Emorivir Favipiravir Lagevrio Molenzavir Molvir Monuvir Paxlovid Ritonavir

Covid (other name Movfor) 200mg

Package	Per Pill	Special Price
200 caps Free Express Delivery	$5.49	~~$1466~~ -26% Only $1097
160 caps Free Express Delivery	$5.60	~~$1173~~ -24% Only $896
120 caps Free Express Delivery	$5.79	~~$880~~ -21% Only $695
80 caps Free Express Delivery	$6.18	~~$587~~ -16% Only $494
40 caps Free Regular Delivery	$7.33	Only $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.